Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

10 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The study will be conducted in two parts:

The purpose of part 1 is to assess the safety and tolerability of irinotecan liposome injection monotherapy and to determine the irinotecan liposome injection monotherapy dose for part 2 of the study.

The purpose of part 2 is to assess irinotecan liposome injection versus intravenous topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy before surgery (neoadjuvant phase), followed by pembrolizumab alone after surgery (adjuvant phase) in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a trial in adult participants with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop grade 3 or higher pneumonitis is ≤10 percent.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase II, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in up to 174 patients with NSCLC exon 20 insertion mutations (87 patients with EGFR exon 20 insertion mutations and 87 patients with HER2 exon 20 insertion mutations).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, multicenter, global phase II basket study of entrectinib (RXDX-101) for the treatment of participants with solid tumors that harbor an NTRK1/2/3, ROS1 or ALK gene fusion. Participants will be assigned to different baskets according to tumor type and gene fusion.

This study will evaluate the safety (side effects) and antitumor activity of study drug in men and women with advanced cancer, based on certain types of DNA defect or damage.